Hollywood, FL, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of hemp cannabinoid, nutraceutical, pharmaceutical, and medical device research and development, receives update from SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, with a price target of $4.12.

View full report: (here)

Report Highlights:

New partnerships and product launches to boost sales
ETST recently entered into a JV with Varsity Group, LLC to use their patented Kanna-Blend formula to develop CBD based e-liquids to be sold under ETST's subsidiary, KannaBidoid Inc. The company has already finalized four product labels for its e-liquids namely 1) Strawberry Lemonade; 2) Lemon Cream; 3) Grape Berry and 4) Apple Pie. These products will start selling by the end of August 2017. ETST has already received pre-orders and plans to sell ~4,000 units in the first batch. The new products will strengthen ETST's presence in the fast growing niche recreational vape/smoke space. The recreational vape/smoke market is projected to grow to $4.77 billion by 2025, at a double digit CAGR during 2015-2025. ETST is also planning to launch the MSN-2 medical device by 1Q18 and has already appointed a communication agency to brand and market the device. The CBD-based pharmaceutical drug portfolio is beginning to see progress with ETST looking to start pre-clinical study for breast cancer treatment and clinical studies for epileptic and non-epileptic seizures by 4Q17.

Agreement with CBDQ for roll out of CBD-based nutraceuticals
ETST has signed an agreement with the Centre de Développement Bioalimentaire du Québec (CDBQ) to develop a manufacturing process for the roll out of three already prototyped CBD-based nutraceuticals which are expected to be launched by the end of 2017. This will provide further traction to revenues.

New distribution channels and aggressive marketing push to yield strong order flow
ETST in a recent update noted that it is on the cusp on finalizing many international distribution channels and partnerships that will provide a further boost to revenue stream within the current CBD product line. Earlier established strategic partnerships with Karmavore Superfood, Forzagen and Smart Medicines will continue to help ETST to diversify product offerings and accelerate entry into new markets. ETST is aggressively spending on marketing via presence in high profile magazines (Natural Awakenings) and web portals (MassRoots). We believe these initiatives will help ETST reach more users, gain major brand recognition, and build early demand for its innovative new products.

Maintaining price target at $4.12
We are maintaining our price target at $4.12 for ETST. The recent JV with Varsity, agreement with CBDQ and launch of Kanna Blend based e-liquids are positive in our view. Also, ETST noted of finalizing new distributors in the international markets. In our last report, we had noted of continued traction in company's CBD products amid new strategic partnerships and new product launches.

SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms.

About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. T To learn more please visit: www.earthsciencetech.com

View ETST's accomplishments and reports on its High-Grade CBD Hemp Oil: (here)

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.
To learn more please visit: www.Earthsciencepharmaceutical.com

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.
To learn more please visit: www.Cannabisthera.com

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by it's unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.
Website coming soon: www.kannabidioidinc.com

About SeeThruEquity: Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.
For more information visit www.seethruequity.com

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations 
Dave Demarest 

Earth Science Tech, Inc. 
Nickolas S. Tabraue, P/D/COO